anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: The straight leg raise (SLR) maneuver, often performed during esophageal manometry, requires patients to lift their leg(s) to augment intraabdominal pressure (IAP). Diverse techniques have been applied for SLR. This study aimed to evaluate and compare the effects of SLR between single and double leg raises.
METHODS: During esophageal manometry, patients were asked to raise one leg, followed by elevating both legs. The efficacy of SLR for (1) detecting hiatal hernia, (2) increasing IAP, and (3) predicting gastroesophageal reflux disease (GERD) with intraesophageal pressure (IEP) was assessed. The value of change in impedance to indicate reflux during SLR in predicting esophageal acid exposure was investigated.
KEY RESULTS: The leg raise procedures were performed in 86 patients undergoing high-resolution esophageal manometry. Both the single and double leg raises exhibited a higher hiatal hernia detection rate compared to the landmark (p = 0.008 and 0.005, respectively). Double leg raise was more effective in raising IAP by >50% compared to single leg raise (100% vs. 65.1%, p < 0.001), increasing yield by 53.6%. The change in IAP showed a positive correlation with the change in IEP during double leg raise (r = 0.31; p = 0.004), higher than that for single leg raise (r = 0.23; p = 0.03). Lower intraesophageal impedance during SLR was associated with AET > 6% with double leg raise (1.5 kΩ vs. 2.5 kΩ, p = 0.04).
CONCLUSIONS & INFERENCES: Our study demonstrates the efficacy of both single and double leg raise maneuvers during HREMI in increasing hiatal hernia detection and possible value in predicting GERD. The double leg raise resulted in a higher rate of effective increase in IAP, potentially enabling more patients to undergo effective SLR during HREMI.
The control group will be comprised of adults 50 and older who report severe or chronic pain, have no prior history of medical marijuana use, can communicate in English, and are willing and able to complete study procedures. The control group will be age, sex, and race matched. The primary study outcome is simulated driving performance (i.e. errors in response time, attention, and executive functioning tasks that predict on-road performance). Secondary outcomes include adverse effects.
The invention relates to a toxin expelling liquid for clearing human body toxins. Clinical experiments for years prove that the formula can safely, quickly and effectively clear various toxins deposited in a human body so as to change the sub-health status of the human body. After the toxin expelling liquid is taken, various indexes such as triglyceride, cholesterol, blood viscosity, blood uric acid, liver function and the like are all improved markedly. A great quantity of medical researches prove that human body toxins, such as most toxin scales of various chemical toxins, heavy metals, drug toxins and fat toxins can not be discharged from an intestinal tract, and the toxins discharged from excrement are mainly harmful substances generated by the self-metabolism of the human body, such as digested food residues, little bile, bacteria, urea and other human body metabolites. The toxin scales in the five internal organs are tightly adhered in the viscera like tea scales and are difficult to discharge along with the excrement, and most toxin scales are continuously accumulated in each viscera organ so as to cause corrosive harm on organs. How to discharge toxin scales in the viscera becomes a widely-concerned topic in the modern medicine field. The traditional Chinese medicine composition disclosed by the invention can be used for discharging harmful toxins in the viscera of the human body and enhancing the immunity function of the human body and reducing and preventing major illnesses such as cardiovascular disease, hepatic disease, diabetes mellitus, cancer and the like and is the best choice for abundant sub-health crowd to discharge the toxin scales.
All patients receive 2 SMT sessions in the first week. This arm also involves 6 additional SMT sessions. Each SMT session is conducted as described previously.
Elimination: Gabapentin is eliminated from the systemic circulation by renal excretion as unchanged drug. Gabapentin is not appreciably metabolized in humans. 

Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing. Gabapentin elimination rate constant, plasma clearance, and renal clearance are directly proportional to creatinine clearance (see  Special Populations: Patients With Renal Insufficiency , below). In elderly patients, and in patients with impaired renal function, gabapentin plasma clearance is reduced. Gabapentin can be removed from plasma by hemodialysis. 

Dosage adjustment in patients with compromised renal function or undergoing hemodialysis is recommended (see DOSAGE AND ADMINISTRATION, Table 6).
A method for making a transdermal drug delivery device for heat sensitive and volatile drugs is disclosed. The device contains a drug-containing adhesive composite layer having an impermeable backing material laminated to the distal surface thereof and a proximal peelable impermeable backing material adapted for removal for administering a drug to the skin or mucosa laminated to the proximal surface thereof. The method comprising the steps of providing first and second adhesive laminates each comprising a drug permeable adhesive layer having laminated to one surface one of said backing materials and having the opposing surface exposed. The drug, in gelled form and optionally containing additives such as enhancers and preservatives, is extruded onto at least one exposed surface of the first or second adhesive laminate followed by laminating together the exposed surfaces of the first and second adhesive laminate such that the adhesive layers and gelled drug are combined to form the drug-containing adhesive composite layer having the distal and proximal surfaces covered by the respective backing materials. The adhesives used in making up the laminates may be the same or different provided the drug is compatible with the adhesive. The process is particularly adaptable to the formulation of nicotine-containing patches. Drug delivery devices made according to the disclosed method and a method of using these drug delivery devices are also described.
The need for endodontic treatment is still very common in the clinical routine, whether due to dento-alveolar trauma or caries. In some cases, the temporary filling procedure is required until the endodontic treatment is completed. The temporary filling material should be biocompatible and bacteriostatic. The aim of this study is through a randomized clinical trial, double blind, split-mouth, evaluate the success rate (contamination rate, periapical lesion relapse and the presence of exudate between the treatment's sessions) of endodontically treated teeth that required filling with temporary material. The composition of the temporary filling material (cement (Based on calcium hydroxide; and based on mineral trioxide aggregate) will be evaluated. Twenty participants with at least two teeth with the need of endodontic treatment will be selected. The teeth will be randomly divided into 2 different groups according to the temporary filling material composition (Based on calcium hydroxide; and based on mineral trioxide aggregate). Data will be collected, tabulated and submitted to statistical analysis.
The investigational product is patient-specific and corresponds to cryopreserved autologous CD34+ cells transduced ex vivo with the pCHIM-p47 vector containing the human p47phox (NCF1) gene in final formulation and container closure system, ready for intended medical use. The starting materials used for the production of the investigational product consist of the viral vector and the patient's CD34+ cells.
The invention relates to a nucleic acid aptamer, in particular to a nucleic acid aptamer H10 with targeting inhibition effect on vibrio anguillarum, and the nucleic acid sequence is shown in SEQ. NO. 1. And the application of the aptamer H10 in preparing Vibrio anguillarum inhibitors. The invention takes vibrio anguillarum as a target, and selects an aptamer (H10) screened by a Cell-SELEX technology to analyze the antibacterial function of the aptamer. Has the advantages of short screening period, simple and convenient chemical synthesis, capability of replacing antibiotics and the like, and has better application prospect. Provides a theoretical basis for further research on inhibitory aptamers.
Histone deacetylase 6 (HDAC6) belongs to the class IIb group of the histone deacetylase family, which participates in remodelling of various tissues. Herein, we sought to examine the potential regulation of HDAC6 in cardiac remodelling post-infarction. Experimental myocardial infarction (MI) was created in HDAC6-deficient (HDAC6-/-) mice and wild-type (HADC6+/+) by left coronary artery ligation. At days 0 and 14 post-MI, we evaluated cardiac function, morphology and molecular endpoints of repair and remodelling. At day 14 after surgery, the ischemic myocardium had increased levels of HADC6 gene and protein of post-MI mice compared to the non-ischemic myocardium of control mice. As compared with HDAC6-/--MI mice, HADC6 deletion markedly improved infarct size and cardiac fibrosis as well as impaired left ventricular ejection fraction and left ventricular fraction shortening. At the molecular levels, HDAC6-/- resulted in a significant reduction in the levels of the transforming growth factor-beta 1 (TGF-β1), phosphor-Smad-2/3, collagen I and collagen III proteins and/or in the ischemic cardiac tissues. All of these beneficial effects were reproduced by a pharmacological inhibition of HADC6 in vivo. In vitro, hypoxic stress increased the expressions of HADC6 and collagen I and III gene; these alterations were significantly prevented by the HADC6 silencing and TubA loading. These findings indicated that HADC6 deficiency resists ischemic injury by a reduction of TGF-β1/Smad2/3 signalling activation, leading to decreased extracellular matrix production, which reduces cardiac fibrosis and dysfunction, providing a potential molecular target in the treatment of patients with MI.
The invention provides an antigen fusion protein and application thereof in preparing vaccines, wherein the fusion polypeptide comprises any one or more of SEQ ID NO. 1, SEQ ID NO. 2 and SEQ ID NO. 3. The invention also provides a recombinant strain, which is used for recombinant expression of the fusion polypeptide. The recombinant lactococcus lactis for recombinant expression of the fusion polypeptide provided by the invention can be used for preparing vaccines, so that immunized animals can resist infection caused by bacteria Mao Junzhu on intestinal tracts.
Standard heparin application will be performed on left side for control on post-op 0th day by the researcher. Intervention with cold application will be performed on the right abdomen site on post-op 1st day. Prior to the intervention, cold silica gel pack which stayed in the freezer for at least 2 hours will be placed on patient's injection site by wrapping up with towel and will be applied on the site for 5 minutes. After 5 minutes, the cold gel pack will be removed from the site and subcutaneous LMWH injection will be applied by the researcher. Following the removal of the injector, cold application will continue for another 2 minutes. Patients' level of pain and satisfaction will be assessed by a nurse working in the clinic with visual analog scale (VAS) after injection.
Carpal tunnel syndrome (CTS) is the most common compression neuropathy. CTS results from the compression of the median nerve in the carpal tunnel. The main symptoms include pain and other unpleasant sensations in hand and wrist. In more advanced stage, weakness and wasting of the thenar and other muscles innervated by median nerve occurs, which may lead to permanent impairment of manual performance. Nerve conduction studies (NCS) remain the method of choice in diagnosing CTS. However ultrasonography (US) is increasingly used along with or instead of NCS. Most frequently, the increase of the cross-sectional area of the median nerve at the inlet to the carpal tunnel is regarded as the marker of CTS. A number of other measurements such as median nerve mobility, volar bulging of flexor retinaculum and others were also studied to increase diagnostic sensitivity and specificity. In this study the investigators aim to assess the utility of measurements made at the point of the maximal stenosis of the median nerve in the tunnel to diagnose CTS. So far, there were only few studies, which visualized the maximal nerve stenosis, which is the essential pathological feature of CTS. In general, the group of patients with CTS and controls will undergo NCS of symptomatic median and ipsilateral ulnar nerves and US of the symptomatic median nerve with measurements of the cross-sectional area, diameter and echogenicity at various points, including the point of the maximal stenosis. The location of the maximal stenosis with respect to external (distal crease) and internal (wrist and hand bones and thenar musculature) will also be evaluated. Subjects will also be asked to fill out the Boston Carpal Tunnel Questionnaire (BCTQ) and a demographic questionnaire. US measurements will be compared between patients and healthy volunteers. US measurements, especially those made at the point of stenosis will be correlated among patients with clinical severity of CTS, reflected by the score in BCTQ and with the grade of electrophysiological severity as introduced by Padua et al. \[1\].
A cosmetic according to the present invention is characterized by containing: a high molecular weight crosslinking agent that is a (meth)acrylic graft silicone having an unsaturated bond and an organopolysiloxane structure in a side chain and having, in the main chain, (meth)acrylic repeating units represented by formulae (I), (II), and (III); and a high molecular weight polymer that is an addition polymer of an organohydrogen polysiloxane represented by general formula (4). Accordingly, provided is a cosmetic that has excellent storage stability and use feeling as a result of having blended therein a high molecular weight polymer having high affinity to a liquid oil solution. (A represents a group selected from alkoxy groups having 1-22 carbon atoms and aryloxy groups having 6-20 carbon atoms. B represents a group having an unsaturated bond represented by formula (1). C represents a group represented by formula (2) or a group represented by (3-1) or (3-2).) (4): M x D y T z Q w
Amlodipine. Rats and mice treated with amlodipine maleate in the diet for up to two years, at concentrations calculated to provide daily dosage levels of amlodipine 0.5, 1.25, and 2.5 mg/kg/day showed no evidence of a carcinogenic effect of the drug. For the mouse, the highest dose was, on a mg/m2 basis, similar to the maximum recommended human dose (MRHD) of amlodipine 10 mg/day. For the rat, the highest dose was, on a mg/m2 basis, about two and a half times the MRHD. (Calculations based on a 60 kg patient.)

Mutagenicity studies conducted with amlodipine maleate revealed no drug related effects at either the gene or chromosome level.

There was no effect on the fertility of rats treated orally with amlodipine maleate (males for 64 days and females for 14 days prior to mating) at doses of amlodipine up to 10 mg/kg/day (about 10 times the MRHD of 10 mg/day on a mg/m2 basis).

Olmesartan medoxomil. Olmesartan was not carcinogenic when administered by dietary administration to rats for up to 2 years. The highest dose tested (2000 mg/kg/day) was, on a mg/m2 basis, about 480 times the maximum recommended human dose (MRHD) of 40 mg/day. Two carcinogenicity studies conducted in mice, a 6-month gavage study in the p53 knockout mouse and a 6-month dietary administration study in the Hras2 transgenic mouse, at doses of up to 1000 mg/kg/day (about 120 times the MRHD), revealed no evidence of a carcinogenic effect of olmesartan. Both olmesartan medoxomil and olmesartan tested negative in the in vitro Syrian hamster embryo cell transformation assay and showed no evidence of genetic toxicity in the Ames (bacterial mutagenicity) test. However, both were shown to induce chromosomal aberrations in cultured cells in vitro (Chinese hamster lung) and tested positive for thymidine kinase mutations in the in vitro mouse lymphoma assay.

Olmesartan medoxomil tested negative in vivo for mutations in the MutaMouse intestine and kidney and for clastogenicity in mouse bone marrow (micronucleus test) at oral doses of up to 2000 mg/kg (olmesartan not tested).

Fertility of rats was unaffected by administration of olmesartan at dose levels as high as 1000 mg/kg/day (240 times the MRHD) in a study in which dosing was begun 2 (female) or 9 (male) weeks prior to mating.
Home-delivered WFPBD meals will be provided to participants, along with nutritional coaching and education. 12 meals a week will be delivered for the first 4 weeks, followed by 6 meals a week for the next 4 weeks. Finally, for the last 18 weeks they will not receive pre-packed meals, but will continue to receive WFPBD coaching. 30 participants are anticipated to be accrued in this arm.
<P>PROBLEM TO BE SOLVED: To provide novel micro-cluster liquid and methods for manufacturing and using them.  <P>SOLUTION: The method for producing micro-cluster liquid comprise causing cavitation of a liquid to form cavitation bubbles under a first pressure followed by depressurization to a second pressure to cause implosion and explosion of the cavitation bubbles such that acoustical energy shockwaves are created. The micro-cluster liquids comprise fractionized or micro-cluster liquids (e.g. water, such as oxygenated micro-cluster water). The micro-cluster water (e.g. oxygenated micro-cluster water) is used to deliver hydration, oxygenation, or agents, such as nutritional agents or medications, and increasing overall cellular performance and exchanging liquids in the cell within minutes of consumption.  <P>COPYRIGHT: (C)2006,JPO&NCIPI
Self-care is the realization of health activities to maintain one's health, life and well-being (14). Self-care power is at different levels in each person and perceptual, cognitive, interpersonal and psychomotor characteristics are needed for an effective self-care power to be formed. Therefore, self-care power varies according to the ability and health status of the individual (12). According to Orem, the development and maintenance of health are the results to be obtained through self-care. Orem's theory also "values personal responsibility for health and indicates that nursing services may have a key role in prevention and health education". Since self-care is a learnable behavior, nurses can encourage and support people's self-care efforts and increase the individual's participation by providing health education (12).

When the literature is examined, there are a limited number of studies examining the effect of back massage on pain in women undergoing hysterectomy surgery. There are studies examining the effect of reiki on pain in different fields (13,14). Pain is a condition that affects all dimensions of the individual including biophysiologic, psychological, sociocultural and political-economic. Although analgesics are indispensable to alleviate postoperative pain, undesirable effects may occur when overused. Therefore, nurses' use of non-drug methods in addition to pharmacologic methods will increase the effectiveness of pharmacologic methods (15). Pharmacology
Deficits of mitochondrial functions have been identified in many human pathologies, in particular in age-related human neurodegenerative diseases. Hence, the molecular causes for mitochondrial dysfunction and potential protection mechanisms have become a major topic in modern cell biology. Apart from defects in their structural integrity, problems in mitochondrial protein biogenesis, including polypeptide transport, folding and assembly to active enzymes, all may result in some degree of functional defects of the organelle. An accumulation of misfolded polypeptides inside mitochondria, confounded by the dual source of mitochondrial polypeptides, will result in the formation of protein aggregates. Such aggregate accumulation bears a cell-toxic potential, resulting in mitochondrial and correlated cellular damages, summarized in the term "aggregate proteotoxicity". Here, we discuss methods to analyze protein aggregation in the mitochondrial matrix compartment. We also address techniques to characterize the biochemical mechanisms that reduce aggregate proteotoxicity, the disaggregation or resolubilization of aggregated polypeptides and the sequestration and neutralization of mitochondrial aggregates at specific sites inside a cell.
The present invention extends to methods, systems, and computer program products for predicting and mitigating athlete injury risk. In general, performance parameter data for athletes can be captured and maintained over time. The performance parameter data can be utilized in at least two different ways. In one aspect, performance parameter data is utilized to detect athletes at increased risk for injury and/or indicate why athletes are at increased risk for injury. In another aspect, performance parameter data is utilized to recommend activities (e.g., training sessions) for athletes that are injured or at increased risk for injury. The recommended activities can reduce athlete injury risk while also minimizing reduction in athlete workload. Recommended activities can be tailored based on injury type, injury severity, risk type, risk level, competition schedule, etc.
VYONDYS 53 is supplied in single-dose vials as a preservative-free concentrated solution that requires dilution prior to administration. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Use aseptic technique. 

  1. Calculate the total dose of VYONDYS 53 to be administered based on the patient's weight and the recommended dose of 30 milligrams per kilogram. Determine the volume of VYONDYS 53 needed and the correct number of vials to supply the full calculated dose. 
  2. Allow the vials to warm to room temperature. Mix the contents of each vial by gently inverting 2 or 3 times. Do not shake. 
  3. Visually inspect each vial of VYONDYS 53. The solution is a clear to slightly opalescent, colorless liquid, and may contain trace amounts of small, white to off-white amorphous particles. Do not use if the solution in the vials is cloudy, discolored or contains extraneous particulate matter other than trace amounts of small, white to off-white amorphous particles. 
  4. With a syringe fitted with a 21-gauge or smaller bore non-coring needle, withdraw the calculated volume of VYONDYS 53 from the appropriate number of vials. 
  5. Dilute the withdrawn VYONDYS 53 in 0.9% Sodium Chloride Injection, USP, to make a total volume of 100 to150 mL. Gently invert 2 to 3 times to mix. Do not shake. Visually inspect the diluted solution. Do not use if the solution is cloudy, discolored or contains extraneous particulate matter other than trace amounts of small, white to off-white amorphous particles. 
  6. Administer the diluted solution via an in-line 0.2 micron filter. 
  7. VYONDYS 53 contains no preservatives and should be administered immediately after dilution. Complete infusion of diluted VYONDYS 53 within 4 hours of dilution. If immediate use is not possible, the diluted product may be stored for up to 24 hours at 2°C to 8°C (36°F to 46°F). Do not freeze. Discard unused VYONDYS 53.